市场调查报告书
商品编码
1268661
2023-2030美国致幻蘑菇市场规模,份额和趋势分析报告,各产品(淋巴球菌属,Chathumnus 属,石松属),形式(干燥,加工),应用(脱瘾,休閒),细分市场预测U.S. Psychedelic Mushroom Market Size, Share & Trends Analysis Report By Product (Psilocybe, Gymnopilus, Panaeolus), By Form (Dried, Processed), By Application (De-addiction, Recreational), And Segment Forecasts, 2023 - 2030 |
根据 Grand View Research, Inc. 的最新报告,美国致幻蘑菇市场规模到 2030 年将达到 43.21 亿美元,2023 年至 2030 年的复合年增长率为 11.3%,预计还会增长。
在美国,致幻蘑菇和其他植物致幻剂的使用正在获得认可,并且越来越多的运动将其使用合法化。 一些城市和州已经将这些物质合法化或合法化,导致兴趣和需求激增。
这些产品在治疗各种精神疾病(例如抑郁症,焦虑症,创伤后应激障碍和成瘾症)方面显示出可喜的效果。 未来,如果对其治疗效果的研究进一步推进,预计需求将进一步增加。
主要用途是治疗抑郁症和焦虑症。 这种蘑菇中的活性成分 psilocybin 已被证明可以缓解抑郁和焦虑的症状,并诱导人格和行为的长期积极变化。 因此,裸盖菇素有望用于治疗其他精神疾病,如 PTSD,成瘾和晚期医学焦虑症。
在美国,人们对心理健康和幸福感的认识不断提高,这是推动致幻蘑菇需求的一个主要因素。 抑郁症和焦虑症等精神疾病的传统疗法并不适用于所有人,导致许多人寻求幻觉疗法等替代疗法。
此外,随着人们对合成药物的潜在风险和副作用的认识不断提高,人们对天然疗法和植物疗法的兴趣也越来越大。 裸盖菇素是一种在致幻蘑菇中发现的天然精神活性化合物,几个世纪以来,土着文化一直将其用于精神病学和治疗目的。 随着人们对自然疗法和替代疗法的兴趣增加,对致幻蘑菇的需求预计将继续增长。
致幻蘑菇也有望用于治疗丛集性头痛,丛集性头痛很严重且通常对常规治疗有抵抗力。 裸盖菇素已被证明可以降低一些患者丛集性头痛的频率和严重程度,为患有这种衰弱性疾病的患者带来新的希望。
The U.S. psychedelic mushroom market size is expected to reach USD 4,321.0 million by 2030, grow at a CAGR of 11.3% from 2023 to 2030 according to a new report by Grand View Research, Inc. The use of psychedelic mushrooms and other plant-based entheogens is gaining acceptance in the U.S., with a growing movement to decriminalize their use. Several cities and states have taken steps to legalize or decriminalize these substances, leading to a surge in interest and demand.
These products have shown promising results in treating various mental health conditions such as depression, anxiety, PTSD, and addiction. As further research is conducted on their therapeutic potential, demand for these substances is likely to increase.
The primary application of these products offer treatment of depression and anxiety disorders. Psilocybin, the active ingredient in these mushrooms, has been found to alleviate symptoms of depression and anxiety and even induce long-term positive changes in personality and behavior. This has sparked growing interest in the use of psilocybin as a potential treatment for other mental health conditions such as PTSD, addiction, and end-of-life anxiety in patients with terminal illnesses.
The growing awareness for mental health and well-being in the U.S. is a major factor driving the demand for psychedelic mushrooms. Traditional treatments for depression, anxiety, and other mental health conditions may not work for everyone, prompting many individuals to seek out alternative therapies, such as psychedelic therapy.
Moreover, there is an increasing interest in natural and plant-based remedies, as people become more aware of the potential risks and side effects of synthetic drugs. Psilocybin, the natural psychoactive compound found in psychedelic mushrooms, has been used for centuries by indigenous cultures for spiritual and therapeutic purposes. As the interest in natural and alternative therapies grows, the demand for psychedelic mushrooms is expected to continue increasing.
Psychedelic mushrooms also offer a potential treatment for cluster headaches, which are severe and often resistant to traditional treatments. Psilocybin has demonstrated effectiveness in reducing the frequency and severity of cluster headaches in some patients, offering new hope for individuals who suffer from this debilitating condition.